Photo of Wayne A. Marasco,  MD, PhD

Wayne A. Marasco, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-2153
Fax: (617) 632-3889


wayne_marasco@dfci.harvard.edu

Wayne A. Marasco, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Professor, Medicine, Harvard Medical School
  • Professor, Cancer Immunology and Virology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research interests are in the field of human antibody engineering and the use of human antibodies in discovery research and in the treatment of human diseases. I am a physician/scientist with clinical training in Infectious Diseases. My clinical subspecialty training is in the care of immunocompromised patients with bone marrow and solid organ transplants and cancer. My clinical practice has had a profound influence on the research conducted in my laboratory at Dana-Farber Cancer Institute. During my rotations on the inpatient Infectious Disease service at BWH/DFCI, I supervise ID fellows and medical residents in the management of infections in immunocompromised patients. As a principal investigator, I supervise two junior faculty, seven post-doctoral fellows/scholars and five research technicians. This supervision involves mentorship roles in bench and clinical research, manuscript review and grant writing. On the national level, I am a member of the AIDS Immunopathogenesis study section and have a leadership role in the organization of and presentation at targeted gene therapy and antibody engineering meetings.

My laboratory is working in the areas of HIV/AIDS, emerging infectious diseases (SARS, highly pathogenic H5N1 avian influenza (bird flu), West Nile Virus (encephalitis), Denge virus (hemorrhagic fever)) and cancer (Adult T-cell Leukemia (HTLV-1), breast CA, renal cell carcinoma (RCC), cutaneous T-cell Lymphoma (CTCL)). This breadth of research is made possible because of two research developments in my laboratory in the field of human antibody engineering. The first is our seminal discovery that human antibodies can not only be used to target proteins on the surface of cells and microbes but can also be used in the form known as intracellular antibodies or intrabodies, which can be delivered to cells by gene transfer techniques. In this way, human antibodies can be expressed in different subcellular compartments inside cells where they can bind to their target protein and modulate its function. The second research development in my laboratory is the construction and characterization of one of the largest human antibody phage display libraries ever made (27 billion members). We have validated the quantity and high quality of the human antibodies that can be obtained from this library through the discoveries that we have made in the research areas mentioned above. Ongoing pre-clinical studies and clinical trials using human monoclonal antibodies (Mabs) are moving forward for the prevention and treatment of SARS and flavivirus diseases including West Nile virus encephalitis. We are also moving forward with a genetic/cellular therapy for the treatment of RCC.

In an effort to greatly expand the use of human monoclonal antibodies (Mab) in the treatment of cancer, I founded the National Foundation of Cancer Research (NFCR) Center for Therapeutic Antibody Engineering (CTAE) (http://www.nfcr-ctae.org/). My CTAE laboratory at Dana-Farber Cancer Institute is working with cancer investigators around the globe to utilize our human antibody library to discover new human Mab for the treatment of cancer. In this way, the CTAE can facilitate a broad range of discovery and translational research in cancer that would not be possible for a single laboratory. This also allows CTAE to work with some of the most accomplished cancer investigators in the world.

www.marascolab.com

Publications

Powered by Harvard Catalyst
  • Avnir Y, Tallarico AS, Zhu Q, Bennett AS, Connelly G, Sheehan J, Sui J, Fahmy A, Huang CY, Cadwell G, Bankston LA, McGuire AT, Stamatatos L, Wagner G, Liddington RC, Marasco WA. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog. 2014; 10:e1004103. PubMed
  • Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, Avnir Y, Tallarico AS, Sheehan J, Zhu Q, Baric RS, Marasco WA. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A 2014. PubMed
  • Hall SR, Jiang Y, Leary E, Yavanian G, Eminli S, O'Neill DW, Marasco WA. Identification and isolation of small CD44-negative mesenchymal stem/progenitor cells from human bone marrow using elutriation and polychromatic flow cytometry. Stem Cells Transl Med 2013; 2:567-78. PubMed
  • Chang DK, Sui J, Geng S, Muvaffak A, Bai M, Fuhlbrigge RC, Lo A, Yammanuru A, Hubbard L, Sheehan J, Campbell JJ, Zhu Q, Kupper TS, Marasco WA. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther 2012; 11:2451-61. PubMed
  • Zhang J, Valianou M, Simmons H, Robinson MK, Lee HO, Mullins SR, Marasco WA, Adams GP, Weiner LM, Cheng JD. Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. FASEB J. 2012. PubMed
  • Han T, Abdel-Motal UM, Chang DK, Sui J, Muvaffak A, Campbell J, Zhu Q, Kupper TS, Marasco WA. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PLoS ONE 2012; 7:e44455. PubMed
  • Vyas JM, Marasco WA. Fatal fulminant hepatic failure from adenovirus in allogeneic bone marrow transplant patients. Case Rep Infect Dis 2012; 2012:463569. PubMed
  • Han T, Marasco WA. Structural basis of influenza virus neutralization. Ann N Y Acad Sci 2011; 1217:178-90. PubMed
  • Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer 2010; 127:598-611. PubMed
  • Xu C, Lo A, Yammanuru A, Tallarico AS, Brady K, Murakami A, Barteneva N, Zhu Q, Marasco WA. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS ONE 2010; 5:e9625. PubMed
  • Nakase K,Cheng J,Zhu Q,Marasco WA. Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. J Leukoc Biol 2008; 85:165-74. PubMed
  • Taube R,Zhu Q,Xu C,Diaz-Griffero F,Sui J,Kamau E,Dwyer M,Aird D,Marasco WA. Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles. PLoS ONE 2008; 3:e3181. PubMed
  • Lo AS, Zhu Q, Marasco WA. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol 2007. PubMed
  • Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25:1421-34. PubMed
  • Li W, Sui J, Huang IC, Kuhn JH, Radoshitzky SR, Marasco WA, Choe H, Farzan M. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology 2007; 367:367-74. PubMed
  • Cheng J, Kydd AR, Nakase K, Noonan KM, Murakami A, Tao H, Dwyer M, Xu C, Zhu Q, Marasco WA. Negative regulation of the SH2-homology-containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 tax oncoprotein. Blood 2007; 110:2110-20. PubMed
  • Xu C, Sui J, Tao H, Zhu Q, Marasco WA. Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-region sulfation, and define CXCR4 antigenic heterogeneity. J Immunol 2007; 179:2408-18. PubMed
  • Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco WA, Liddington RC. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem 2006; 281:34610-6. PubMed
  • Kanai R, Kar K, Anthony K, Gould LH, Ledizet M, Fikrig E, Marasco WA, Koski RA, Modis Y. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol 2006; 80:11000-8. PubMed
  • Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 2006; 348:1245-53. PubMed
  • Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP. Development of engineered antibodies specific for the Mlerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther 2006; 5:2096-105. PubMed
  • Tarnovitski N, Matthews LJ, Sui J, Gershoni JM, Marasco WA. Mapping a Neutralizing Epitope on the SARS Coronavirus Spike Protein: Computational Prediction Based on Affinity-selected Peptides. J Mol Biol 2006; 359:190-201. PubMed
  • Si Z, Vandegraaff N, O'huigin C, Song B, Yuan W, Xu C, Perron M, Li X, Marasco WA, Engelman A, Dean M, Sodroski J. Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc Natl Acad Sci U S A 2006; 103:7454-9. PubMed
  • Gould LH, Sui J, Foellmer H, Oliphant T, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, de Silva AM, Diamond MS, Koski RA, Marasco WA, Fikrig E. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 2005; 79:14606-13. PubMed
  • Qin C, Wang J, Wei Q, She M, Marasco WA, Jiang H, Tu X, Zhu H, Ren L, Gao H, Guo L, Huang L, Yang R, Cong Z, Guo L, Wang Y, Liu Y, Sun Y, Duan S, Qu J, Chen L, Tong W, Ruan L, Liu P, Zhang H, Zhang J, Zhang H, Liu D, Liu Q, Hong T, He W. An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol 2005; 206:251-9. PubMed
  • Bal HP, Cheng J, Murakami A, Tallarico AS, Wang W, Zhou D, Vasicek TJ, Marasco WA. GITR overexpression on CD4+CD25+ HTLV-1 transformed cells: detection by massively parallel signature sequencing. Biochem Biophys Res Commun 2005; 332:569-84. PubMed
  • Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23:709-17. PubMed
  • Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M, Marasco WA. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol 2005; 79:5900-6. PubMed
  • Marasco WA. Therapeutic antibody gene transfer. Nat Biotechnol 2005; 23:551-2. PubMed
  • Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005; 24:1634-43. PubMed
  • Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005; 65:2344-52. PubMed
  • Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Cusi MG, Micheli L, Gennari F, Siccardi A, Marasco WA, Pal. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther 2004; 12:299-310. PubMed
  • Busch A, Marasco WA, Doebis C, Volk HD, Seifert M. MHC class I manipulation on cell surfaces by gene transfer of anti-MHC class I intrabodies--a tool for decreased immunogenicity of allogeneic tissue and cell transplants. Methods 2004; 34:240-9. PubMed
  • Beyer F, Doebis C, Busch A, Ritter T, Mhashilkar A, Marasco WM, Laube H, Volk HD, Seifert M. Decline of surface MHC I by adenoviral gene transfer of anti-MHC I intrabodies in human endothelial cells-new perspectives for the generation of universal donor cells for tissue transplantation. J Gene Med 2004; 6:616-23. PubMed
  • Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004; 101:2536-41. PubMed
  • Gennari F, Mehta S, Wang Y, St Clair Tallarico A, Palu G, Marasco WA. Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. J Mol Biol 2003; 335:193-207. PubMed
  • Cheng J, Zhang D, Zhou C, Marasco WA. Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells. Leuk Res 2003; 28:71-82. PubMed
  • Sui J, Bai J, St Clair Tallarico A, Xu C, Marasco WA. Identification of CD4 and transferrin receptor antibodies by CXCR4 antibody-guided Pathfinder selection. Eur J Biochem 2003; 270:4497-506. PubMed
  • Zhang D, Murakami A, Johnson RP, Sui J, Cheng J, Bai J, Marasco WA. Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies. J Acquir Immune Defic Syndr 2003; 32:245-54. PubMed
  • Bai J, Sui J, Zhu RY, Tallarico AS, Gennari F, Zhang D, Marasco WA. Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem 2002; 278:1433-42. PubMed
  • Sui J, Marasco WA. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 2002; 303:9-14. PubMed
  • Mhashilkar AM, Doebis C, Seifert M, Busch A, Zani C, Soo Hoo J, Nagy M, Ritter T, Volk HD, Marasco WA. Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes. Gene Ther 2002; 9:307-19. PubMed
  • Li X, Josef J, Marasco WA. Hiv-1 Tat can substantially enhance the capacity of NIK to induce IkappaB degradation. Biochem Biophys Res Commun 2001; 286:587-94. PubMed
  • Ogueta SB, Yao F, Marasco WA. Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector. Mol Med 2001; 7:569-79. PubMed
  • Li X, Stuckert P, Bosch I, Marks JD, Marasco WA. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther 2001; 8:555-65. PubMed
  • Marasco WA. Intrabodies as antiviral agents. Curr Top Microbiol Immunol 2001; 260:247-70. PubMed
  • Li X, Multon MC, Henin Y, Schweighoffer F, Venot C, Josef J, Zhou C, LaVecchio J, Stuckert P, Raab M, Mhashilkar A, Tocque B, Marasco WA. Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc. J Biol Chem 2000; 275:30925-33. PubMed
  • Li X, Multon MC, Henin Y, Schweighoffer F, Venot C, LaVecchio J, Josef J, Stuckert P, Mhashilkar A, Tocqu. Upregulation of the apoptosis-associated protein Grb3-3 in HIV-1-infected human CD4(+) lymphocytes. Biochem Biophys Res Commun 2000; 276:362-70. PubMed
  • Mirzabekov T, Kontos H, Farzan M, Marasco W, Sodroski J. Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol 2000; 18:649-54. PubMed
  • Song SU, Marasco WA. Rapid establishment of myeloma cell lines expressing Fab(Tac)-protamine, a targetable protein vector, directed against high-affinity alpha-chain of human interleukin-2 receptor. Methods Mol Biol 1999; 133:157-66. PubMed
  • Marasco WA, LaVecchio J, Winkler A. Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Methods 2000; 231:223-38. PubMed
  • Zhu Q, Zeng C, Huhalov A, Yao J, Turi TG, Danley D, Hynes T, Cong Y, DiMattia D, Kennedy S, Daumy G, Schaeffer E, Marasco WA, Huston JS. Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J Immunol Methods 2000; 231:207-22. PubMed
  • Poznansky MC, La Vecchio J, Silva-Arietta S, Porter-Brooks J, Brody K, Olszak IT, Adams GB, Ramstedt U, Marasco WA, Scadden DT. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat. Hum Gene Ther 1999; 10:2505-14. PubMed
  • Mhashilkar AM, LaVecchio J, Eberhardt B, Porter-Brooks J, Boisot S, Dove JH, Pumphrey C, Li X, Weissmahr RN, Ring DB, Ramstedt U, Marasco WA. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodie Hum Gene Ther 1999; 10:1453-67. PubMed
  • Marasco WA, Chen S, Richardson JH, Ramstedt U, Jones SD. Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Hum Gene Ther 1998; 9:1627-42. PubMed
  • Richardson JH, Hofmann W, Sodroski JG, Marasco WA. Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene Ther 1998; 5:635-44. PubMed
  • Marasco WA, Dana Jones S. Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression. Adv Drug Deliv Rev 2000; 31:153-170. PubMed
  • Poznansky MC, Foxall R, Mhashilkar A, Coker R, Jones S, Ramstedt U, Marasco W. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum Gene Ther 1998; 9:487-96. PubMed
  • Vallat AV, De Girolami U, He J, Mhashilkar A, Marasco W, Shi B, Gray F, Bell J, Keohane C, Smith TW, Gabuzda D. Localization of HIV-1 co-receptors CCR5 and CXCR4 in the brain of children with AIDS. Am J Pathol 1998; 152:167-78. PubMed
  • Richardson JH, Waldmann TA, Sodroski JG, Marasco WA. Inducible knockout of the interleukin-2 receptor alpha chain: expression of the high-affinity IL-2 receptor is not required for the in vitro growth of HTLV-I-transformed cell lines. Virology 1997; 237:209-16. PubMed
  • Mhashilkar AM, Biswas DK, LaVecchio J, Pardee AB, Marasco WA. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists. J Virol 1997; 71:6486-94. PubMed
  • Levin R, Mhashilkar AM, Dorfman T, Bukovsky A, Zani C, Bagley J, Hinkula J, Niedrig M, Albert J, Wahren B, G. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Mol Med 1997; 3:96-110. PubMed
  • Marasco WA. Intrabodies: turning the humoral immune system outside in for intracellular immunization. Gene Ther 1997; 4:11-5. PubMed
  • Rondon IJ, Marasco WA. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol 1997; 51:257-83. PubMed
  • Chen JD, Yang Q, Yang AG, Marasco WA, Chen SY. Intra- and extracellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody. Hum Gene Ther 1996; 7:1515-25. PubMed
  • Chen SY, Marasco WA. Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Semin Oncol 1996; 23:148-53. PubMed
  • Richardson JH, Marasco WA. Intracellular antibodies: development and therapeutic potential. Trends Biotechnol 1995; 13:306-10. PubMed
  • Marasco WA. Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology 1997; 1:1-19. PubMed
  • Richardson JH, Sodroski JG, Waldmann TA, Marasco WA. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci U S A 1995; 92:3137-41. PubMed
  • Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 1995; 14:1542-51. PubMed
  • Chen SY, Zani C, Khouri Y, Marasco WA. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther 1995; 2:116-23. PubMed
  • Khouri YF, McIntosh K, Cavacini L, Posner M, Pagano M, Tuomala R, Marasco WA. Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. J Clin Invest 1995; 95:732-7. PubMed
  • Bagley J, Dillon PJ, Rosen C, Robinson J, Sodroski J, Marasco WA. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120. Mol Immunol 1994; 31:1149-60. PubMed
  • Chen SY, Khouri Y, Bagley J, Marasco WA. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci U S A 1994; 91:5932-6. PubMed
  • Chen SY, Bagley J, Marasco WA. Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther 1994; 5:595-601. PubMed
  • Marasco WA, Szilvay AM, Kalland KH, Helland DG, Reyes HM, Walter RJ. Spatial association of HIV-1 tat protein and the nucleolar transport protein B23 in stably transfected Jurkat T-cells. Arch Virol 1994; 139:133-54. PubMed
  • Marasco WA, Haseltine WA, Chen SY. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci U S A 1993; 90:7889-93. PubMed
  • Marasco WA, Bagley J, Zani C, Posner M, Cavacini L, Haseltine WA, Sodroski J. Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. J Clin Invest 1992; 90:1467-78. PubMed
  • Garcia LW, Hemphill RB, Marasco WA, Ciano PS. Acquired immunodeficiency syndrome with disseminated toxoplasmosis presenting as an acute pulmonary and gastrointestinal illness. Arch Pathol Lab Med 1991; 115:459-63. PubMed
  • Bradley SF, Gordon JJ, Baumgartner DD, Marasco WA, Kauffman CA. Group C streptococcal bacteremia: analysis of 88 cases. Rev Infect Dis 1991; 13:270-80. PubMed
  • Sannomiya P, Craig RA, Clewell DB, Suzuki A, Fujino M, Till GO, Marasco WA. Characterization of a class of nonformylated Enterococcus faecalis-derived neutrophil chemotactic peptides: the sex pheromones. Proc Natl Acad Sci U S A 1990; 87:66-70. PubMed
  • Janeczek AH, Marasco WA, van Alten PJ, Walter RJ. Autoradiographic analysis of formylpeptide chemoattractant binding, uptake and intracellular processing by neutrophils. J Cell Sci 1989; 94 ( Pt 1):155-68. PubMed
  • Marasco WA, Lester S, Parsonnet J. Unusual presentation of cat scratch disease in a patient positive for antibody to the human immunodeficiency virus. Rev Infect Dis 1989; 11:793-803. PubMed
  • Feltner DE, Marasco WA. Regulation of formyl peptide receptor binding to rabbit neutrophil plasma membranes. Use of monovalent cations, guanine nucleotides, and bacterial toxins to discriminate among different states of the receptor. J Immunol 1989; 142:3963-70. PubMed
  • Atkinson YH, Lopez AF, Marasco WA, Lucas CM, Wong GG, Burns GF, Vadas MA. Recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) regulates f Met-Leu-Phe receptors on human neutrophils. Immunology 1988; 64:519-25. PubMed
  • Atkinson YH, Marasco WA, Lopez AF, Vadas MA. Recombinant human tumor necrosis factor-alpha. Regulation of N-formylmethionylleucylphenylalanine receptor affinity and function on human neutrophils. J Clin Invest 1988; 81:759-65. PubMed
  • Marasco WA, Ward PA. Chemotactic factors of bacterial origin. Methods Enzymol 1987; 162:198-214. PubMed
  • Marasco WA, Gikas PW, Azziz-Baumgartner R, Hyzy R, Eldredge CJ, Stross J. Ibuprofen-associated renal dysfunction. Pathophysiologic mechanisms of acute renal failure, hyperkalemia, tubular necrosis, and proteinuria. Arch Intern Med 1987; 147:2107-16. PubMed
  • Walter RJ, Marasco WA. Direct visualization of formylpeptide receptor binding on rounded and polarized human neutrophils: cellular and receptor heterogeneity. J Leukoc Biol 1987; 41:377-91. PubMed
  • Feltner DE, Smith RH, Marasco WA. Characterization of the plasma membrane bound GTPase from rabbit neutrophils. I. Evidence for an Ni-like protein coupled to the formyl peptide, C5a, and leukotriene B4 chemotaxis receptors. J Immunol 1986; 137:1961-70. PubMed
  • Duque RE, Fantone JC, Kramer C, Marasco WA, Phan SH. Inhibition of neutrophil activation by p-bromophenacyl bromide and its effects on phospholipase A2. Br J Pharmacol 1986; 88:463-72. PubMed
  • Marasco WA, Becker KM, Feltner DE, Brown CS, Ward PA, Nairn R. Covalent affinity labeling, detergent solubilization, and fluid-phase characterization of the rabbit neutrophil formyl peptide chemotaxis receptor. Biochemistry 1985; 24:2227-36. PubMed
  • Marasco WA, Ward PA, Feltner DE, Varani J. Chemotactic factor binding by metastatic tumour cells: evidence for a formyl-peptide receptor on a non-myelogenous cell. J Cell Sci 1985; 73:121-34. PubMed
  • Nairn R, Smith RH, Brown CS, Marasco WA. What are the molecular characteristics of the neutrophil receptor for chemotactic formylated peptides? Surv Immunol Res 1984; 4:213-9. PubMed
  • Marasco WA, Feltner DE, Ward PA. Formyl peptide chemotaxis receptors on the rat neutrophil: experimental evidence for negative cooperativity. J Cell Biochem 1984; 27:359-75. PubMed
  • Walter RJ, Marasco WA. Localization of chemotactic peptide receptors on rabbit neutrophils. Exp Cell Res 1984; 154:613-8. PubMed
  • Marasco WA, Phan SH, Krutzsch H, Showell HJ, Feltner DE, Nairn R, Becker EL, Ward PA. Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem 1984; 259:5430-9. PubMed
  • Fantone JC, Marasco WA, Elgas LJ, Ward PA. Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production. Am J Pathol 1984; 115:9-16. PubMed
  • Kunkel SL, Manderino GL, Marasco W, Kaercher K, Hirata AA, Ward PA. A specific enzyme-linked immunosorbent assay (ELISA) for the determination of human C5a antigen. J Immunol Methods 1983; 62:305-14. PubMed
  • Marasco WA, Fantone JC, Freer RJ, Ward PA. Characterization of the rat neutrophil formyl peptide chemotaxis receptor. Am J Pathol 1983; 111:273-81. PubMed
  • Fantone JC, Marasco WA, Elgas LJ, Ward PA. Anti-inflammatory effects of prostaglandin E1: in vivo modulation of the formyl peptide chemotactic receptor on the rat neutrophil. J Immunol 1983; 130:1495-7. PubMed
  • Marasco WA, Fantone JC, Ward PA. Spasmogenic activity of chemotactic N-formylated oligopeptides: identity of structure--function relationships for chemotactic and spasmogenic activities. Proc Natl Acad Sci U S A 1982; 79:7470-3. PubMed
  • Marasco WA, Becker EL. Anti-idiotype as antibody against the formyl peptide chemotaxis receptor of the neutrophil. J Immunol 1982; 128:963-8. PubMed
  • Marasco WA, Showell HJ, Freer RJ, Becker EL. Anti-f Met-Leu-Phe: similarities in fine specificity with the formyl peptide chemotaxis receptor of the neutrophil. J Immunol 1982; 128:956-62. PubMed
  • Marasco WA, Showell HJ, Becker EL. Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil. Biochem Biophys Res Commun 1981; 99:1065-72. PubMed
  • Marasco WA, Becker EL, Oliver JM. The ionic basis of chemotaxis. Separate cation requirements for neutrophil orientation and locomotion in a gradient of chemotactic peptide. Am J Pathol 1980; 98:749-68. PubMed
Hide